Nearly 5% of patients with cancer die within 1 month of undergoing surgery
the ONA take:
According to new findings presented at the American Society of Clinical Oncology's (ASCO's) 2014 Quality Care Symposium in Boston, Massachusetts, researchers have found that of the more than 1.1 million patients with cancer who underwent surgery, nearly 5% died within 1 month of their surgery.
For the study, the researchers identified more than 1.1 million patients diagnosed with cancer between 2004 and 2001. Of those, 53,498 patients died within the month after undergoing the operation.
In addition, researchers found that married patients had a 20% lower risk of dying within 1 month after surgery compared to unmarried patients. Insured patients had a 12% lower risk of dying within 1 month after surgery compared with uninsured patients, and wealthier patients had a 5% lower risk.
Also, more educated patients had a 2% lower risk of dying compared with less educated patients. In contrast, minority patients had a 13% higher risk of dying within 1 month after surgery, men had an 11% higher risk, and older patients had a 2% higher risk. Patients with advanced cancer had an 89% greater risk of dying within 1 month after surgery. The findings suggest that disparities affect adversely affect surgical outcomes.
Of more than 1.1 million patientswho underwent surgery, nearly 5% died within 1 month.
In a study of more than 1.1 million cancer patients who had surgery, Harvard researchers found that almost 5 percent died within one month of their operation. These findings are scheduled to be presented at the American Society of Clinical Oncology's 2014 Quality Care Symposium, held from Oct. 17 to 18 in Boston. The researchers found that, of the 1.1 million patients diagnosed from 2004 to 2011, 53,498 died within the month after surgery.
Specifically, married patients had a 20 percent lower risk of dying within the month after surgery; insured patients had a 12 percent lower risk; wealthier patients had a 5 percent lower risk; and more-educated patients had a 2 percent lower risk. Conversely, minority patients had a 13 percent higher risk of dying; men had an 11 percent greater risk; older patients had a 2 percent greater risk; and patients with advanced cancer had an 89 percent higher risk.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|